Ravi Botla, MD
Gastroenterology · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 43 years
- Graduated 1983
Offices
1 location · Dignity Health Medical Foundation · 1,211 clinicians in this group
Looking this up.
Hospitals listed: Mark Twain Medical Center · St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Botla’s office at (209) 546-5200 to ask if they take your plan before you enroll.
State licence records
1 licence
- Texas J7912Physician License · since 1995 · expires 2028-02-28ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mark Twain Medical CenterSan Andreas, CACritical Access Hospital · Voluntary non-profit - Other · No emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
See every measure and the patient survey for Mark Twain Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 9.3 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.9 · 116 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 353 cases | None | Jul 2024 – Jun 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 81.9 · 54 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33.7 · 108 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4 to 9.3) · 54 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (7.3 to 14.2) · 54 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.4) · 375 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 89 cases | No different | Jan 2024 – Dec 2024 |
What patients said (151 patients answered, 22% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 89% |
| Nurses "always" communicated well | 90% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 85% |
| Nurses "always" listened carefully | 91% |
| Nurses "always" treated them with courtesy and respect | 93% |
| "Always" quiet at night | 65% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 60% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$29,538
Medicare paid this office $29,538 for 148 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 49 | $4,995 | $100 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,375 | $199 |
| New patient visit (45+ min) | 32 | $4,170 | $130 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,064 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,348 | $62 |
See all 8 services
| Return visit (30+ min) | 49 | $4,995 | $100 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,375 | $199 |
| New patient visit (45+ min) | 32 | $4,170 | $130 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,064 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,348 | $62 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $2,237 | $86 |
| Biopsy of large bowel using a flexible endoscope | 14 | $1,055 | $75 |
| New patient visit (30+ min) | 11 | $990 | $90 |
Procedures Medicare counted
| Colonoscopy | 114 | More than 83% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 147 | More than 85% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 113 | 82 | 89 | 96 | 102 | 26 |
| Biopsy of large bowel using a flexible endoscope | 115 | 76 | 97 | 106 | 92 | 14 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 46 | 33 | 43 | 45 | 52 | 22 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | 14 | 22 | 22 | 19 | – |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | – | – | 11 | – | – |
| Insertion of stomach tube using a flexible endoscope | – | – | 12 | 13 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
148 Original Medicare patients in 2024. Average age 72 · Under 65 11% · 85 and older 9% · Women 63% · Also on Medicaid 38% · Health risk score 1.42. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 41% · Coronary heart disease 35% · Chronic kidney disease 33% · Heart failure 25% · Depression 24% · COPD 23% · Atrial fibrillation 22% · Cancer 18% · Stroke 11%.
The office billed $197,522, Medicare allowed $37,002 and paid $29,538; for 280 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 148 | 280 | 72 | 1.42 | $197,522 | $29,538 |
| 2023 | 482 | 1,781 | 73 | 1.85 | $527,408 | $121,383 |
| 2022 | 506 | 1,146 | 72 | 1.83 | $438,100 | $101,781 |
| 2021 | 489 | 1,242 | 72 | 1.90 | $456,379 | $111,393 |
| 2020 | 468 | 1,088 | 72 | 2.50 | $369,213 | $84,517 |
| 2019 | 578 | 1,421 | 70 | 2.53 | $512,073 | $117,812 |
| 2018 | 573 | 1,431 | 70 | 2.56 | $537,705 | $122,473 |
| 2017 | 569 | 1,546 | 71 | 2.28 | $549,818 | $129,075 |
| 2016 | 594 | 1,757 | 71 | 2.57 | $537,988 | $140,234 |
| 2015 | 831 | 2,500 | 71 | 2.66 | $598,165 | $194,822 |
| 2014 | 745 | 2,382 | 70 | 2.80 | $536,479 | $179,735 |
| 2013 | 668 | 2,252 | 70 | 2.90 | $496,081 | $164,373 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Return visit (30+ min) | 194 | $22,533 | $85 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 41 | $14,722 | $36 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 41 | $10,683 | $48 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 52 | $9,881 | $190 |
| Short return visit (20+ min) | 133 | $9,640 | $60 |
| Biopsy of large bowel using a flexible endoscope | 92 | $8,224 | $89 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 100 | $7,676 | $75 |
| New patient visit (45+ min) | 61 | $6,343 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $4,787 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $3,825 | $98 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 18 | $3,042 | $169 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 11 | $1,922 | $37 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,454 | $77 |
| New patient visit (30+ min) | 16 | $1,280 | $80 |
| Short return visit | 12 | $430 | $36 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 13 | $186 | $14 |
2022: 14 services
| Return visit (30+ min) | 178 | $23,151 | $89 |
| Short return visit (20+ min) | 192 | $14,110 | $59 |
| Biopsy of large bowel using a flexible endoscope | 106 | $11,752 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 45 | $8,623 | $192 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 95 | $7,532 | $78 |
| New patient visit (45+ min) | 65 | $6,561 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $5,828 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,359 | $99 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 15 | $2,639 | $176 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,117 | $176 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $2,022 | $92 |
| Insertion of stomach tube using a flexible endoscope | 13 | $1,981 | $152 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,426 | $130 |
| New patient visit (30+ min) | 17 | $1,216 | $72 |
2021: 13 services
| Return visit (30+ min) | 201 | $28,774 | $93 |
| Short return visit (20+ min) | 173 | $12,667 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $9,795 | $54 |
| Biopsy of large bowel using a flexible endoscope | 96 | $9,048 | $93 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 43 | $8,496 | $198 |
| New patient visit (45+ min) | 62 | $7,610 | $123 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 68 | $7,574 | $105 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 88 | $6,792 | $76 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $1,982 | $180 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $1,939 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,862 | $155 |
| Insertion of stomach tube using a flexible endoscope | 12 | $1,705 | $142 |
| New patient visit (30+ min) | 12 | $787 | $66 |
2020: 12 services
| Short return visit (20+ min) | 218 | $15,969 | $49 |
| Return visit (30+ min) | 101 | $7,857 | $69 |
| Biopsy of large bowel using a flexible endoscope | 76 | $7,423 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 80 | $7,277 | $55 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 81 | $6,958 | $85 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $6,556 | $199 |
| New patient visit (45+ min) | 57 | $6,417 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $5,900 | $151 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $4,879 | $104 |
| Short return visit | 49 | $1,800 | $35 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,224 | $87 |
| New patient visit (30+ min) | 17 | $1,096 | $64 |
2019: 13 services
| Short return visit (20+ min) | 304 | $24,540 | $50 |
| Biopsy of large bowel using a flexible endoscope | 115 | $12,417 | $108 |
| New patient visit (45+ min) | 109 | $12,107 | $111 |
| Return visit (30+ min) | 124 | $11,687 | $76 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 111 | $9,458 | $84 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 46 | $9,171 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $7,519 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $6,793 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $3,440 | $104 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $2,799 | $140 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,556 | $86 |
| New patient visit (30+ min) | 16 | $1,207 | $75 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | $141 | $13 |
2018: 11 services
| Short return visit (20+ min) | 263 | $19,271 | $50 |
| Return visit (30+ min) | 163 | $16,307 | $77 |
| Biopsy of large bowel using a flexible endoscope | 118 | $13,103 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $13,033 | $155 |
| New patient visit (45+ min) | 106 | $12,098 | $114 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 129 | $11,009 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 90 | $8,770 | $55 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 45 | $8,666 | $193 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 12 | $2,196 | $183 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,613 | $90 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,191 | $92 |
2017: 15 services
| Short return visit (20+ min) | 276 | $21,176 | $47 |
| Return visit (30+ min) | 155 | $16,439 | $75 |
| Biopsy of large bowel using a flexible endoscope | 146 | $14,268 | $97 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 66 | $13,670 | $201 |
| New patient visit (45+ min) | 109 | $12,083 | $111 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 125 | $10,498 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 84 | $8,103 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $7,056 | $153 |
| Diagnostic exam of large bowel using a flexible endoscope | 24 | $3,146 | $131 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $2,733 | $91 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,498 | $89 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,069 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $1,903 | $79 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | $1,788 | $163 |
| New patient visit (30+ min) | 18 | $1,313 | $73 |
2016: 18 services
| Return visit (30+ min) | 186 | $19,263 | $70 |
| Short return visit (20+ min) | 248 | $17,743 | $50 |
| Biopsy of large bowel using a flexible endoscope | 132 | $13,185 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 127 | $12,271 | $54 |
| New patient visit (45+ min) | 108 | $12,212 | $112 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 139 | $12,128 | $86 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 58 | $12,038 | $204 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 55 | $5,685 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,641 | $155 |
| Diagnostic exam of large bowel using a flexible endoscope | 25 | $3,596 | $138 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $2,819 | $188 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $2,632 | $85 |
| Insertion of stomach tube using a flexible endoscope | 16 | $2,589 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $2,541 | $77 |
| Pathology examination of tissue using a microscope, intermediate complexity | 25 | $1,720 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 16 | $1,289 | $50 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $959 | $40 |
| New patient visit (30+ min) | 17 | $956 | $56 |
2015: 26 services
| Return visit (30+ min) | 210 | $23,184 | $76 |
| Short return visit (20+ min) | 254 | $17,806 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 160 | $15,986 | $54 |
| New patient visit (45+ min) | 137 | $14,948 | $109 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 149 | $13,880 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 130 | $13,450 | $101 |
| Biopsy of large bowel using a flexible endoscope | 88 | $12,659 | $144 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $8,420 | $228 |
| Diagnostic exam of large bowel using a flexible endoscope | 49 | $7,592 | $155 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $5,817 | $149 |
| Colonoscopy, flexible; proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare tehnique | 23 | $5,721 | $249 |
| Insertion of stomach tube using a flexible endoscope | 31 | $5,020 | $162 |
| Pathology examination of tissue using a microscope, intermediate complexity | 93 | $4,986 | $24 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 48 | $4,841 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $4,499 | $79 |
| Special stained specimen slides to examine tissue, initial procedure | 48 | $3,160 | $38 |
| Special stained specimen slides to examine tissue including interpretation and report | 50 | $2,923 | $38 |
| New patient visit (30+ min) | 35 | $2,454 | $70 |
| Long return visit (40+ min) | 17 | $1,951 | $108 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,801 | $150 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 48 | $1,536 | $30 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 11 | $1,379 | $125 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 14 | $1,241 | $48 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $921 | $77 |
| Limited ultrasound scan of abdomen | 13 | $579 | $45 |
| Short return visit | 14 | $417 | $30 |
2014: 20 services
| Return visit (30+ min) | 200 | $23,572 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 204 | $19,807 | $55 |
| Short return visit (20+ min) | 229 | $16,638 | $51 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 126 | $13,480 | $103 |
| New patient visit (45+ min) | 103 | $11,965 | $116 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 126 | $11,889 | $92 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 42 | $9,464 | $225 |
| Removal of polyps or growths in large bowel using an endoscope | 37 | $9,258 | $250 |
| Biopsy of large bowel using a flexible endoscope | 70 | $7,983 | $114 |
| Pathology examination of tissue using a microscope, intermediate complexity | 124 | $6,241 | $24 |
| Diagnostic exam of large bowel using a flexible endoscope | 39 | $5,958 | $149 |
| Insertion of stomach tube using a flexible endoscope | 30 | $5,183 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,166 | $154 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $3,942 | $99 |
| Special stained specimen slides to examine tissue including interpretation and report | 66 | $3,624 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $3,262 | $78 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 65 | $2,732 | $41 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 77 | $2,516 | $30 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 21 | $1,283 | $40 |
| Limited ultrasound scan of abdomen | 12 | $691 | $58 |
2013: 21 services
| Short return visit (20+ min) | 254 | $22,635 | $49 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 172 | $17,522 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 175 | $16,527 | $53 |
| Removal of polyps or growths in large bowel using an endoscope | 52 | $12,866 | $247 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 106 | $11,621 | $109 |
| Return visit (30+ min) | 105 | $10,073 | $77 |
| New patient visit (45+ min) | 88 | $9,692 | $110 |
| Insertion of stomach tube using a flexible endoscope | 43 | $8,667 | $193 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $8,342 | $220 |
| Diagnostic exam of large bowel using a flexible endoscope | 47 | $6,510 | $139 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 122 | $4,690 | $29 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,315 | $105 |
| Biopsy of large bowel using a flexible endoscope | 48 | $4,261 | $87 |
| Pathology examination of tissue using a microscope, intermediate complexity | 65 | $3,463 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 36 | $2,838 | $53 |
| Pathology examination of tissue using a microscope, intermediate complexity | 35 | $1,592 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 18 | $1,307 | $52 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,071 | $76 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 22 | $253 | $11 |
| Blood test, comprehensive group of blood chemicals | 17 | $243 | $14 |
| Insertion of needle into vein for collection of blood sample | 26 | $89 | $3 |
Medicaid work
$3,807 in 2023
Medicaid paid $3,807 for 83 billed services this clinician did in 2023, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 83 | $3,807 |
| 2023 | 83 | 1 | 17 | $3,807 |
| 2022 | 151 | 2 | 21 | $5,678 |
| 2021 | 168 | 2 | 24 | $5,178 |
| 2020 | 16 | 1 | 15 | $183 |
| 2019 | 25 | 1 | 13 | $32 |
| 2018 | 18 | 1 | 16 | $0 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 127 | $5,228 |
| Short return visit (20+ min) | 24 | $450 |
2021
| Return visit (30+ min) | 141 | $4,363 |
| Short return visit (20+ min) | 27 | $815 |
2020
| Short return visit (20+ min) | 16 | $183 |
2019
| Short return visit (20+ min) | 25 | $32 |
2018
| Short return visit (20+ min) | 18 | $0 |
Drugs they prescribed that Part D paid
$119,278
Pharmacies billed $119,278 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
671 generic and 129 brand-name prescriptions · $119,278 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 76 | $63,999 | $842 |
| Lubiprostone | 17 | $2,795 | $164 |
| Pantoprazole | 271 | $2,293 | $8 |
| Sod Sulf-Potass Sulf-Mag Sulf | 16 | $1,074 | $67 |
| Cholestyramine | 14 | $958 | $68 |
See all 14 drugs
| Linzess | 76 | $63,999 | $842 |
| Lubiprostone | 17 | $2,795 | $164 |
| Pantoprazole | 271 | $2,293 | $8 |
| Sod Sulf-Potass Sulf-Mag Sulf | 16 | $1,074 | $67 |
| Cholestyramine | 14 | $958 | $68 |
| Omeprazole | 60 | $918 | $15 |
| Esomeprazole Magnesium | 22 | $881 | $40 |
| Famotidine | 62 | $792 | $13 |
| Lactulose | 13 | $421 | $32 |
| Constulose | 21 | $416 | $20 |
| Dicyclomine | 47 | $375 | $8 |
| Propranolol | 24 | $272 | $11 |
| Spironolactone | 11 | $153 | $14 |
| Metoclopramide | 16 | $62 | $4 |
Year by year
| 2024 | 800 | 302 | None | 16% | $119,278 |
| 2023 | 2,927 | 842 | None | 18% | $478,420 |
| 2022 | 2,526 | 727 | None | 20% | $420,632 |
| 2021 | 2,356 | 653 | None | 26% | $582,442 |
| 2020 | 2,420 | 596 | None | 24% | $701,972 |
| 2019 | 2,492 | 708 | None | None | $537,345 |
| 2018 | 2,365 | 648 | None | 24% | $734,317 |
| 2017 | 2,239 | 669 | 1% (23) | 25% | $1,131,538 |
| 2016 | 1,996 | 571 | 1% (19) | None | $1,024,790 |
| 2015 | 2,106 | 593 | 1% (21) | 29% | $1,318,944 |
| 2014 | 2,005 | 547 | 1% (22) | None | $311,449 |
| 2013 | 1,837 | 548 | 1% (14) | None | $182,523 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Linzess | 219 | $158,398 | $723 |
| Viberzi | 14 | $23,068 | $1,648 |
| Lubiprostone | 63 | $15,443 | $245 |
| Creon | 12 | $13,325 | $1,110 |
| Dexlansoprazole Dr | 20 | $13,011 | $651 |
| Pantoprazole | 756 | $9,148 | $12 |
| Clenpiq | 51 | $8,374 | $164 |
| Mesalamine Er | 16 | $6,566 | $410 |
| Mesalamine | 14 | $5,957 | $426 |
| Plenvu | 41 | $5,951 | $145 |
| Sucralfate | 74 | $5,118 | $69 |
| Esomeprazole Magnesium | 62 | $4,446 | $72 |
| Cholestyramine | 51 | $3,938 | $77 |
| Gavilyte-G | 224 | $3,893 | $17 |
| Ursodiol | 31 | $3,541 | $114 |
| Sutab | 21 | $3,526 | $168 |
| Constulose | 113 | $2,836 | $25 |
| Dicyclomine | 220 | $2,672 | $12 |
| Omeprazole | 165 | $2,207 | $13 |
| Famotidine | 151 | $2,178 | $14 |
| Lactulose | 76 | $2,161 | $28 |
| Cholestyramine Light | 13 | $1,687 | $130 |
| Enulose | 25 | $1,453 | $58 |
| Peg-3350 and Electrolytes | 71 | $1,330 | $19 |
| Diphenoxylate-Atropine | 46 | $1,241 | $27 |
| Sod Sulf-Potass Sulf-Mag Sulf | 13 | $942 | $72 |
| Metoclopramide | 82 | $912 | $11 |
| Propranolol | 32 | $845 | $26 |
| Spironolactone | 31 | $614 | $20 |
| Peg 3350-Electrolyte | 13 | $319 | $25 |
| Ondansetron Odt | 21 | $314 | $15 |
| Hydrocortisone | 22 | $305 | $14 |
| Furosemide | 27 | $169 | $6 |
| Metronidazole | 13 | $89 | $7 |
2022: 30 drugs
| Linzess | 216 | $146,567 | $679 |
| Viberzi | 13 | $20,299 | $1,561 |
| Mesalamine | 12 | $16,232 | $1,353 |
| Lubiprostone | 29 | $8,998 | $310 |
| Pantoprazole | 720 | $8,134 | $11 |
| Cholestyramine | 44 | $7,021 | $160 |
| Clenpiq | 44 | $6,863 | $156 |
| Dexlansoprazole Dr | 13 | $6,555 | $504 |
| Suprep | 38 | $4,279 | $113 |
| Ursodiol | 25 | $3,442 | $138 |
| Plenvu | 22 | $2,883 | $131 |
| Lactulose | 78 | $2,811 | $36 |
| Peg-3350 and Electrolytes | 151 | $2,515 | $17 |
| Sucralfate | 67 | $2,170 | $32 |
| Omeprazole | 155 | $2,100 | $14 |
| Esomeprazole Magnesium | 39 | $1,715 | $44 |
| Diphenoxylate-Atropine | 57 | $1,532 | $27 |
| Famotidine | 138 | $1,514 | $11 |
| Constulose | 70 | $1,432 | $20 |
| Dicyclomine | 159 | $1,242 | $8 |
| Gavilyte-G | 62 | $942 | $15 |
| Metoclopramide | 85 | $868 | $10 |
| Propranolol | 21 | $838 | $40 |
| Spironolactone | 27 | $600 | $22 |
| Peg 3350-Electrolyte | 21 | $579 | $28 |
| Clarithromycin | 12 | $434 | $36 |
| Ondansetron | 28 | $375 | $13 |
| Hydrocortisone | 12 | $326 | $27 |
| Amoxicillin | 13 | $149 | $11 |
| Furosemide | 24 | $75 | $3 |
2021: 32 drugs
| Linzess | 173 | $104,266 | $603 |
| Xifaxan | 14 | $40,691 | $2,906 |
| Dexilant | 35 | $26,648 | $761 |
| Suprep | 202 | $22,512 | $111 |
| Viberzi | 14 | $20,634 | $1,474 |
| Lubiprostone | 33 | $12,915 | $391 |
| Mesalamine Er | 16 | $10,757 | $672 |
| Amitiza | 22 | $9,067 | $412 |
| Pantoprazole | 552 | $7,170 | $13 |
| Cholestyramine | 36 | $5,727 | $159 |
| Sucralfate | 63 | $2,889 | $46 |
| Esomeprazole Magnesium | 35 | $2,687 | $77 |
| Famotidine | 180 | $2,499 | $14 |
| Dicyclomine | 198 | $1,943 | $10 |
| Ursodiol | 20 | $1,901 | $95 |
| Clenpiq | 12 | $1,852 | $154 |
| Diphenoxylate-Atropine | 56 | $1,706 | $30 |
| Constulose | 97 | $1,700 | $18 |
| Omeprazole | 128 | $1,559 | $12 |
| Lactulose | 40 | $835 | $21 |
| Metoclopramide | 56 | $696 | $12 |
| Propranolol | 33 | $530 | $16 |
| Ondansetron | 34 | $455 | $13 |
| Spironolactone | 30 | $434 | $14 |
| Peg-3350 and Electrolytes | 26 | $375 | $14 |
| Azathioprine | 14 | $308 | $22 |
| Peg 3350-Electrolyte | 16 | $290 | $18 |
| Nadolol | 14 | $202 | $14 |
| Lansoprazole | 13 | $201 | $15 |
| Gavilyte-G | 12 | $147 | $12 |
| Amoxicillin | 11 | $102 | $9 |
| Furosemide | 20 | $40 | $2 |
2020: 28 drugs
| Linzess | 157 | $83,265 | $530 |
| Humira | 12 | $65,421 | $5,452 |
| Amitiza | 73 | $32,210 | $441 |
| Dexilant | 44 | $27,772 | $631 |
| Viberzi | 16 | $22,035 | $1,377 |
| Suprep | 186 | $19,528 | $105 |
| Pantoprazole | 628 | $7,768 | $12 |
| Cholestyramine | 53 | $7,376 | $139 |
| Ursodiol | 21 | $3,117 | $148 |
| Esomeprazole Magnesium | 42 | $2,697 | $64 |
| Dicyclomine | 216 | $1,982 | $9 |
| Famotidine | 158 | $1,863 | $12 |
| Sucralfate | 32 | $1,860 | $58 |
| Lactulose | 67 | $1,751 | $26 |
| Diphenoxylate-Atropine | 69 | $1,569 | $23 |
| Omeprazole | 150 | $1,463 | $10 |
| Nadolol | 14 | $997 | $71 |
| Propranolol | 49 | $833 | $17 |
| Constulose | 47 | $714 | $15 |
| Azathioprine | 13 | $636 | $49 |
| Hydrocortisone | 12 | $417 | $35 |
| Ondansetron | 35 | $360 | $10 |
| Lansoprazole | 16 | $338 | $21 |
| Gavilyte-G | 26 | $321 | $12 |
| Metoclopramide | 58 | $286 | $5 |
| Spironolactone | 30 | $265 | $9 |
| Amoxicillin | 11 | $68 | $6 |
| Furosemide | 19 | $46 | $2 |
2019: 30 drugs
| Linzess | 115 | $56,161 | $488 |
| Humira | 11 | $55,838 | $5,076 |
| Amitiza | 87 | $37,969 | $436 |
| Suprep | 241 | $24,173 | $100 |
| Dexilant | 41 | $23,444 | $572 |
| Apriso | 20 | $19,277 | $964 |
| Cholestyramine | 74 | $10,628 | $144 |
| Pantoprazole | 515 | $5,404 | $10 |
| Ursodiol | 20 | $4,362 | $218 |
| Mesalamine | 14 | $3,889 | $278 |
| Lactulose | 99 | $2,057 | $21 |
| Famotidine | 178 | $1,915 | $11 |
| Omeprazole | 177 | $1,835 | $10 |
| Diphenoxylate-Atropine | 66 | $1,299 | $20 |
| Propranolol | 52 | $1,254 | $24 |
| Esomeprazole Magnesium | 24 | $1,239 | $52 |
| Dicyclomine | 203 | $1,210 | $6 |
| Gavilyte-G | 86 | $1,190 | $14 |
| Ondansetron | 31 | $968 | $31 |
| Nadolol | 13 | $934 | $72 |
| Azathioprine | 27 | $866 | $32 |
| Hydrocortisone | 16 | $760 | $48 |
| Ranitidine | 26 | $675 | $26 |
| Constulose | 38 | $674 | $18 |
| Sucralfate | 28 | $634 | $23 |
| Metoclopramide | 60 | $336 | $6 |
| Spironolactone | 13 | $133 | $10 |
| Metronidazole | 15 | $124 | $8 |
| Amoxicillin | 12 | $65 | $5 |
| Prednisone | 13 | $43 | $3 |
2018: 34 drugs
| Humira | 13 | $64,192 | $4,938 |
| Humira | 12 | $59,238 | $4,937 |
| Xifaxan | 26 | $54,052 | $2,079 |
| Linzess | 92 | $41,518 | $451 |
| Amitiza | 63 | $26,250 | $417 |
| Dexilant | 56 | $24,764 | $442 |
| Apriso | 21 | $18,739 | $892 |
| Suprep | 180 | $16,889 | $94 |
| Cholestyramine | 62 | $8,581 | $138 |
| Mesalamine | 12 | $4,262 | $355 |
| Esomeprazole Magnesium | 24 | $3,956 | $165 |
| Pantoprazole | 487 | $3,952 | $8 |
| Lactulose | 105 | $2,123 | $20 |
| Ursodiol | 14 | $2,123 | $152 |
| Polyethylene Glycol 3350 | 32 | $1,295 | $40 |
| Omeprazole | 143 | $1,231 | $9 |
| Nadolol | 14 | $1,146 | $82 |
| Famotidine | 128 | $1,044 | $8 |
| Gavilyte-G | 74 | $971 | $13 |
| Diphenoxylate-Atropine | 49 | $967 | $20 |
| Constulose | 56 | $878 | $16 |
| Dicyclomine | 186 | $807 | $4 |
| Sucralfate | 37 | $771 | $21 |
| Azathioprine | 26 | $743 | $29 |
| Propranolol | 44 | $690 | $16 |
| Generlac | 24 | $593 | $25 |
| Proctosol-Hc | 11 | $531 | $48 |
| Ranitidine | 22 | $498 | $23 |
| Metoclopramide | 75 | $497 | $7 |
| Hydrocortisone | 15 | $373 | $25 |
| Ondansetron Odt | 29 | $258 | $9 |
| Spironolactone | 20 | $185 | $9 |
| Ondansetron | 15 | $109 | $7 |
| Metronidazole | 11 | $89 | $8 |
2017: 30 drugs
| Humira | 13 | $58,828 | $4,525 |
| Xifaxan | 12 | $27,754 | $2,313 |
| Linzess | 74 | $27,418 | $371 |
| Dexilant | 68 | $25,267 | $372 |
| Amitiza | 50 | $17,576 | $352 |
| Suprep | 196 | $17,137 | $87 |
| Apriso | 22 | $13,226 | $601 |
| Cholestyramine | 61 | $8,011 | $131 |
| Lactulose | 179 | $3,581 | $20 |
| Esomeprazole Magnesium | 29 | $3,368 | $116 |
| Pantoprazole | 350 | $2,825 | $8 |
| Nadolol | 27 | $1,893 | $70 |
| Gavilyte-G | 137 | $1,707 | $12 |
| Polyethylene Glycol 3350 | 42 | $1,238 | $29 |
| Omeprazole | 142 | $1,136 | $8 |
| Azathioprine | 36 | $1,069 | $30 |
| Propranolol | 40 | $681 | $17 |
| Generlac | 38 | $645 | $17 |
| Dicyclomine | 139 | $558 | $4 |
| Sucralfate | 27 | $526 | $19 |
| Diphenoxylate-Atropine | 23 | $460 | $20 |
| Mycophenolate Mofetil | 11 | $447 | $41 |
| Metoclopramide | 94 | $435 | $5 |
| Famotidine | 62 | $300 | $5 |
| Peg-3350 and Electrolytes | 19 | $241 | $13 |
| Metronidazole | 18 | $211 | $12 |
| Ranitidine | 14 | $182 | $13 |
| Spironolactone | 23 | $153 | $7 |
| Ondansetron Odt | 14 | $127 | $9 |
| Tramadol | 22 | $68 | $3 |
2016: 37 drugs
| Harvoni | 12 | $411,915 | $34,326 |
| Humira | 14 | $55,957 | $3,997 |
| Xifaxan | 16 | $28,467 | $1,779 |
| Linzess | 84 | $28,030 | $334 |
| Dexilant | 52 | $18,044 | $347 |
| Amitiza | 50 | $17,381 | $348 |
| Apriso | 32 | $13,343 | $417 |
| Cholestyramine | 56 | $6,703 | $120 |
| Suprep | 62 | $5,163 | $83 |
| Nexium | 16 | $4,094 | $256 |
| Carafate | 12 | $3,854 | $321 |
| Ursodiol | 15 | $3,538 | $236 |
| Lactulose | 171 | $3,043 | $18 |
| Esomeprazole Magnesium | 22 | $2,745 | $125 |
| Nadolol | 35 | $2,446 | $70 |
| Prevalite | 12 | $2,178 | $182 |
| Gavilyte-G | 159 | $2,173 | $14 |
| Omeprazole | 174 | $1,572 | $9 |
| Pantoprazole | 242 | $1,499 | $6 |
| Generlac | 58 | $1,276 | $22 |
| Azathioprine | 30 | $1,042 | $35 |
| Polyethylene Glycol 3350 | 38 | $1,011 | $27 |
| Sucralfate | 37 | $762 | $21 |
| Proctozone-Hc | 14 | $750 | $54 |
| Ranitidine | 16 | $672 | $42 |
| Propranolol | 30 | $607 | $20 |
| Peg-3350 and Electrolytes | 36 | $446 | $12 |
| Dicyclomine | 93 | $398 | $4 |
| Diphenoxylate-Atropine | 22 | $385 | $18 |
| Metoclopramide | 74 | $329 | $4 |
| Famotidine | 50 | $312 | $6 |
| Gavilyte-N | 12 | $190 | $16 |
| Spironolactone | 20 | $155 | $8 |
| Tramadol | 17 | $80 | $5 |
| Ondansetron | 11 | $72 | $7 |
| Isosorbide Mononitrate Er | 12 | $53 | $4 |
| Furosemide | 15 | $31 | $2 |
2015: 42 drugs
| Harvoni | 21 | $703,439 | $33,497 |
| Xifaxan | 39 | $63,672 | $1,633 |
| Humira | 14 | $44,918 | $3,208 |
| Amitiza | 67 | $22,775 | $340 |
| Dexilant | 65 | $19,371 | $298 |
| Linzess | 48 | $15,035 | $313 |
| Nexium | 48 | $13,194 | $275 |
| Pentasa | 15 | $8,864 | $591 |
| Moviprep | 103 | $8,331 | $81 |
| Apriso | 21 | $7,080 | $337 |
| Cholestyramine | 44 | $5,228 | $119 |
| Carafate | 20 | $3,331 | $167 |
| Ursodiol | 12 | $3,213 | $268 |
| Lactulose | 159 | $3,002 | $19 |
| Esomeprazole Magnesium | 14 | $2,679 | $191 |
| Omeprazole | 185 | $1,800 | $10 |
| Nadolol | 24 | $1,723 | $72 |
| Pantoprazole | 193 | $1,698 | $9 |
| Gavilyte-G | 124 | $1,639 | $13 |
| Lansoprazole | 25 | $1,299 | $52 |
| Suprep | 15 | $1,218 | $81 |
| Polyethylene Glycol 3350 | 41 | $1,151 | $28 |
| Generlac | 71 | $1,106 | $16 |
| Mycophenolate Mofetil | 22 | $937 | $43 |
| Proctozone-Hc | 19 | $757 | $40 |
| Dicyclomine | 154 | $703 | $5 |
| Sucralfate | 26 | $640 | $25 |
| Ranitidine | 17 | $619 | $36 |
| Proctosol-Hc | 11 | $536 | $49 |
| Azathioprine | 17 | $535 | $31 |
| Metoclopramide | 72 | $423 | $6 |
| Metronidazole | 34 | $371 | $11 |
| Peg-3350 and Electrolytes | 29 | $369 | $13 |
| Diphenoxylate-Atropine | 20 | $297 | $15 |
| Famotidine | 52 | $283 | $5 |
| Spironolactone | 27 | $226 | $8 |
| Propranolol | 16 | $198 | $12 |
| Peg 3350-Electrolyte | 18 | $185 | $10 |
| Ciprofloxacin | 14 | $75 | $5 |
| Tramadol | 14 | $57 | $4 |
| Furosemide | 20 | $55 | $3 |
| Isosorbide Mononitrate Er | 11 | $44 | $4 |
2014: 34 drugs
| Xifaxan | 30 | $42,507 | $1,417 |
| Humira | 13 | $34,931 | $2,687 |
| Amitiza | 101 | $29,643 | $293 |
| Nexium | 59 | $19,049 | $323 |
| Dexilant | 81 | $19,028 | $235 |
| Linzess | 48 | $12,117 | $252 |
| Pentasa | 18 | $9,459 | $526 |
| Moviprep | 100 | $7,956 | $80 |
| Apriso | 28 | $7,260 | $259 |
| Cholestyramine | 35 | $4,044 | $116 |
| Omeprazole | 211 | $3,707 | $18 |
| Lactulose | 170 | $3,246 | $19 |
| Nadolol | 50 | $3,138 | $63 |
| Carafate | 17 | $2,755 | $162 |
| Pantoprazole | 176 | $2,046 | $12 |
| Suprep | 25 | $1,960 | $78 |
| Ursodiol | 11 | $1,474 | $134 |
| Lansoprazole | 20 | $1,420 | $71 |
| Polyethylene Glycol 3350 | 31 | $1,213 | $39 |
| Generlac | 63 | $1,198 | $19 |
| Gavilyte-G | 60 | $865 | $14 |
| Proctozone-Hc | 36 | $667 | $19 |
| Sucralfate | 28 | $641 | $23 |
| Metoclopramide | 75 | $589 | $8 |
| Peg-3350 and Electrolytes | 36 | $520 | $14 |
| Spironolactone | 44 | $487 | $11 |
| Metronidazole | 39 | $474 | $12 |
| Dicyclomine | 73 | $378 | $5 |
| Famotidine | 52 | $301 | $6 |
| Diphenoxylate-Atropine | 19 | $276 | $15 |
| Peg 3350-Electrolyte | 13 | $135 | $10 |
| Hydrocodone-Acetaminophen | 12 | $102 | $8 |
| Amoxicillin | 14 | $100 | $7 |
| Furosemide | 29 | $93 | $3 |
2013: 33 drugs
| Xifaxan | 25 | $33,287 | $1,331 |
| Humira | 13 | $30,141 | $2,319 |
| Amitiza | 85 | $23,443 | $276 |
| Dexilant | 107 | $22,564 | $211 |
| Nexium | 75 | $19,309 | $257 |
| Apriso | 14 | $4,560 | $326 |
| Omeprazole | 211 | $3,780 | $18 |
| Lactulose | 159 | $3,692 | $23 |
| Suprep | 37 | $2,721 | $74 |
| Moviprep | 37 | $2,669 | $72 |
| Nadolol | 36 | $1,737 | $48 |
| Pantoprazole | 149 | $1,713 | $11 |
| Cholestyramine | 24 | $1,635 | $68 |
| Generlac | 60 | $1,464 | $24 |
| Polyethylene Glycol 3350 | 32 | $1,404 | $44 |
| Peg-3350 and Electrolytes | 76 | $1,192 | $16 |
| Gavilyte-G | 72 | $1,067 | $15 |
| Sucralfate | 41 | $911 | $22 |
| Kristalose | 11 | $856 | $78 |
| Clarithromycin | 11 | $802 | $73 |
| Metronidazole | 52 | $661 | $13 |
| Metoclopramide | 63 | $531 | $8 |
| Spironolactone | 30 | $411 | $14 |
| Dicyclomine | 81 | $358 | $4 |
| Famotidine | 37 | $242 | $7 |
| Peg-3350 With Flavor Packs | 12 | $235 | $20 |
| Ranitidine | 13 | $234 | $18 |
| Proctozone-Hc | 17 | $233 | $14 |
| Peg 3350-Electrolyte | 19 | $222 | $12 |
| Amoxicillin | 16 | $135 | $8 |
| Diphenoxylate-Atropine | 12 | $106 | $9 |
| Furosemide | 25 | $97 | $4 |
| Ciprofloxacin | 14 | $74 | $5 |
Money from drug and device companies
$142 in 2024
| 2024 | 3 | 4 | None | $142 |
| 2023 | 10 | 36 | None | $817 |
| 2022 | 7 | 33 | None | $621 |
| 2021 | 7 | 25 | None | $484 |
| 2020 | 3 | 4 | None | $61 |
| 2019 | 8 | 14 | None | $538 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
GastroGPO, LLC
$25,816
Held by this doctor · 2024, 2023, 2022, 2021 · Common Stock
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Gilead Sciences | Livdelzi | $89 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $39 | 2 payments
|
| Celgene | Zeposia | $15 | 1 payment
|
See all 4 published payments
| Gilead Sciences | Meals · 2024-11-06 | Livdelzi | $89 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2024-01-30 | Xifaxan | $18 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2024-01-09 | Trulance | $21 |
| Celgene | Meals · 2024-01-04 | Zeposia | $15 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $817
| AbbVie | Rinvoq | $425 | 22 payments
|
| Axonics | Axonics | $116 | 1 payment
|
| Genzyme | Dupixent | $88 | 3 payments
|
| Nestle Healthcare Nutrition | Zenpep | $45 | 3 payments
|
| Janssen Biotech | Stelara | $39 | 1 payment
|
| Celgene | Zeposia | $34 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $21 | 1 payment
|
| Lilly USA | None | $18 | 1 payment
|
| Gilead Sciences | None | $17 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $14 | 1 payment
|
2022: $621
| Abbvie | Mavyret | $325 | 22 payments
|
| Genzyme | Dupixent | $181 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $50 | 4 payments
|
| Janssen Biotech | Remicade | $20 | 1 payment
|
| RedHill Biopharma | Talicia | $16 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $15 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Gattex | $14 | 1 payment
|
2021: $484
| AbbVie | Linzess | $309 | 17 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $65 | 1 payment
|
| Gilead Sciences | None | $51 | 3 payments
|
| Janssen Biotech | Remicade | $21 | 1 payment
|
| Evoke Pharma | Gimoti | $14 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $12 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $12 | 1 payment
|
2020: $61
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $34 | 2 payments
|
| Cumberland Pharmaceuticals | Omeclamox-Pak | $15 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $12 | 1 payment
|
2019: $538
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $247 | 5 payments
|
| Intercept Pharmaceuticals | Ocaliva | $120 | 1 payment
|
| AbbVie | None | $78 | 1 payment
|
| Ferring Pharmaceuticals | Clenpiq | $35 | 3 payments
|
| Shionogi | Mulpleta | $17 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Amitiza | $15 | 1 payment
|
| Gilead Sciences | None | $14 | 1 payment
|
| Janssen Biotech | Stelara | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Allergan Inc. · A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2019 | Their institution | $20,519 |
| Allergan, Inc. · A 46-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Longterm Study With A 6-Week Randomized-Withdrawal Period To Evaluate the Safety and · 2020 | Their institution | $6,415 |
| Allergan Inc. · 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2019 | Their institution | $6,008 |
| Allergan Inc. · A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2019 | Their institution | $3,322 |
| Allergan, Inc. · A 52-Week, Double Blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients With Diabetic Gastroparesis · 2021 | Their institution | $3,156 |
| Allergan, Inc. · A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2020 | Their institution | $1,999 |
| Allergan, Inc. · A 52-Week, Double Blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients With Diabetic Gastroparesis · 2020 | Their institution | $1,634 |
| Allergan, Inc. · 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2020 | Their institution | $1,518 |
| Allergan, Inc. · 46 Weeks, Placebo Controlled (Pts From 01/02 Studies Roll Over for 53 Weeks Total Exposure) · 2021 | Their institution | $1,000 |
| Allergan, Inc. · A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2021 | Their institution | $1,000 |
| Allergan, Inc. · A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis · 2020 | Their institution | $788 |
| Allergan Inc. · 46 Weeks, Placebo Controlled Pts From 0102 Studies Roll Over for 53 Weeks Total Exposure · 2019 | Their institution | $250 |
| Allergan Inc. · A 52-Week, Double Blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients With Diabetic Gastroparesis · 2019 | Their institution | $250 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 79.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1366540544
- Licence
- TX J7912Texas J7912: Active
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 136549604
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- Po Box 75235, Dallas, TX, 75235
- NPI first listed
- 2006-09-20
- NPI last updated
- 2017-02-22
This is when the NPI record was last certified, not a medical board exam.